Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
The University of Texas MD Anderson Cancer Center · University of Oklahoma Medical Center · +39 more institutions
Abstract
PURPOSE Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit in mismatch repair (MMR)–deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve outcomes, especially in pMMR disease. METHODS This phase III, global, double-blind, placebo-controlled trial randomly assigned eligible patients with newly diagnosed advanced or recurrent endometrial cancer 1:1:1 to: carboplatin/paclitaxel plus durvalumab placebo followed by placebo maintenance (control arm); carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab plus olaparib placebo (durvalumab arm); or carboplatin/paclitaxel plus durvalumab…
Citation impact
- FWCI
- 82.32
- Percentile
- 100%
- References
- 18
Authors
256Topics & keywords
- Durvalumab
- Medicine
- Olaparib
- Internal medicine
- Oncology
- Carboplatin
- Placebo
- Urology
- Good health and well-being
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- GSGilead Sciences
- RPRegeneron Pharmaceuticals
- JPJazz Pharmaceuticals
- PTPTC Therapeutics
- COClovis Oncology
- MTMersana Therapeutics
- MGMyriad Genetics
- NONRG Oncology
- NBNGM Biopharmaceuticals
- EEQRx
- SSeagen
- EEisai
- MBMereo BioPharma
- GGenentech
- PPharmacyclics
- DSDaiichi Sankyo Europe